Spark, D.L., Fornito, A., Langmead, C.J. et al. Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics. Transl Psychiatry 12, 147 (2022). https://doi.org/10.1038/s41398-022-01904-2
6447874 {6447874:UMDGH5LK} items 1 chicago-author-date 0 default asc 6931 https://butwhatdoweknow.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-89a9418f1def1a2b7ae2fc9e2125f865%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22UMDGH5LK%22%2C%22library%22%3A%7B%22id%22%3A6447874%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Spark%20et%20al.%22%2C%22parsedDate%22%3A%222022-04-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESpark%2C%20Daisy%20L.%2C%20Alex%20Fornito%2C%20Christopher%20J.%20Langmead%2C%20and%20Gregory%20D.%20Stewart.%202022.%20%26%23x201C%3BBeyond%20Antipsychotics%3A%20A%20Twenty-First%20Century%20Update%20for%20Preclinical%20Development%20of%20Schizophrenia%20Therapeutics.%26%23x201D%3B%20%3Ci%3ETranslational%20Psychiatry%3C%5C%2Fi%3E%2012%20%281%29%3A%201%26%23x2013%3B11.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41398-022-01904-2%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41398-022-01904-2%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Beyond%20antipsychotics%3A%20a%20twenty-first%20century%20update%20for%20preclinical%20development%20of%20schizophrenia%20therapeutics%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daisy%20L.%22%2C%22lastName%22%3A%22Spark%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alex%22%2C%22lastName%22%3A%22Fornito%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20J.%22%2C%22lastName%22%3A%22Langmead%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20D.%22%2C%22lastName%22%3A%22Stewart%22%7D%5D%2C%22abstractNote%22%3A%22Despite%2050%2B%20years%20of%20drug%20discovery%2C%20current%20antipsychotics%20have%20limited%20efficacy%20against%20negative%20and%20cognitive%20symptoms%20of%20schizophrenia%2C%20and%20are%20ineffective%5Cu2014with%20the%20exception%20of%20clozapine%5Cu2014against%20any%20symptom%20domain%20for%20patients%20who%20are%20treatment%20resistant.%20Novel%20therapeutics%20with%20diverse%20non-dopamine%20D2%20receptor%20targets%20have%20been%20explored%20extensively%20in%20clinical%20trials%2C%20yet%20often%20fail%20due%20to%20a%20lack%20of%20efficacy%20despite%20showing%20promise%20in%20preclinical%20development.%20This%20lack%20of%20translation%20between%20preclinical%20and%20clinical%20efficacy%20suggests%20a%20systematic%20failure%20in%20current%20methods%20that%20determine%20efficacy%20in%20preclinical%20rodent%20models.%20In%20this%20review%2C%20we%20critically%20evaluate%20rodent%20models%20and%20behavioural%20tests%20used%20to%20determine%20preclinical%20efficacy%2C%20and%20look%20to%20clinical%20research%20to%20provide%20a%20roadmap%20for%20developing%20improved%20translational%20measures.%20We%20highlight%20the%20dependence%20of%20preclinical%20models%20and%20tests%20on%20dopamine-centric%20theories%20of%20dysfunction%20and%20how%20this%20has%20contributed%20towards%20a%20self-reinforcing%20loop%20away%20from%20clinically%20meaningful%20predictions%20of%20efficacy.%20We%20review%20recent%20clinical%20findings%20of%20distinct%20dopamine-mediated%20dysfunction%20of%20corticostriatal%20circuits%20in%20patients%20with%20treatment-resistant%20vs.%20non-treatment-resistant%20schizophrenia%20and%20suggest%20criteria%20for%20establishing%20rodent%20models%20to%20reflect%20such%20differences%2C%20with%20a%20focus%20on%20objective%2C%20translational%20measures.%20Finally%2C%20we%20review%20current%20schizophrenia%20drug%20discovery%20and%20propose%20a%20framework%20where%20preclinical%20models%20are%20validated%20against%20objective%2C%20clinically%20informed%20measures%20and%20preclinical%20tests%20of%20efficacy%20map%20onto%20those%20used%20clinically.%22%2C%22date%22%3A%222022-04-07%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41398-022-01904-2%22%2C%22ISSN%22%3A%222158-3188%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41398-022-01904-2%22%2C%22collections%22%3A%5B%22AWT385HL%22%5D%2C%22dateModified%22%3A%222022-08-10T13%3A14%3A30Z%22%7D%7D%5D%7D
Spark, Daisy L., Alex Fornito, Christopher J. Langmead, and Gregory D. Stewart. 2022. “Beyond Antipsychotics: A Twenty-First Century Update for Preclinical Development of Schizophrenia Therapeutics.” Translational Psychiatry 12 (1): 1–11. https://doi.org/10.1038/s41398-022-01904-2.
